Axon Capital LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$9,099	4
2024	Research	$119,208	16
2023	Research	$135,731	10
2022	Research	$41,466	4
2021	Research	$51,915	6

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $168,254 14 payments
Sumitomo Pharma America, Inc. $94,612 13 payments
Galderma Laboratories, L.P. $30,369 2 payments
Pfizer Inc. $29,788 4 payments
Chiesi USA, Inc. $18,000 1 payment
GlaxoSmithKline, LLC. $16,395 6 payments

Studies the money was for Research payments · program years 2021–2025

An Open-Label 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $63,984 2 payments
A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $58,881 6 payments
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $33,155 2 payments
A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $30,059 2 payments
A Phase 3 Singlearm Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age $29,788 4 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $25,734 2 payments
Serene $20,737 2 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab $20,119 1 payment
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $18,000 1 payment
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $16,395 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.